<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: The $68 Billion Pfizer-Wyeth Deal Won&#039;t Revive the Moribund Merger Market</title>
	<atom:link href="http://moneymorning.com/2009/02/02/pfizer-wyeth/feed/" rel="self" type="application/rss+xml" />
	<link>http://moneymorning.com/2009/02/02/pfizer-wyeth/</link>
	<description>Global Investment News</description>
	<lastBuildDate>Fri, 25 May 2012 18:42:41 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
	<item>
		<title>By: Is Washington Replacing Wall Street as the City That Drives America?</title>
		<link>http://moneymorning.com/2009/02/02/pfizer-wyeth/comment-page-1/#comment-5114</link>
		<dc:creator>Is Washington Replacing Wall Street as the City That Drives America?</dc:creator>
		<pubDate>Wed, 18 Mar 2009 18:31:51 +0000</pubDate>
		<guid isPermaLink="false">http://www.moneymorning.com/?p=4629#comment-5114</guid>
		<description>[...] Wyeth (WYE) for $68 billion [For two related stories in today&#8217;s issue of Money Morning, check out this analysis of the Pfizer/Wyeth deal itself; or click here to read our evaluation on the outlook for the [...]</description>
		<content:encoded><![CDATA[<p>[...] Wyeth (WYE) for $68 billion [For two related stories in today&rsquo;s issue of Money Morning, check out this analysis of the Pfizer/Wyeth deal itself; or click here to read our evaluation on the outlook for the [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Roche Keeps M&#38;A Party Rolling with $46.8 Billion Deal for Genentech</title>
		<link>http://moneymorning.com/2009/02/02/pfizer-wyeth/comment-page-1/#comment-5113</link>
		<dc:creator>Roche Keeps M&#38;A Party Rolling with $46.8 Billion Deal for Genentech</dc:creator>
		<pubDate>Fri, 13 Mar 2009 09:26:06 +0000</pubDate>
		<guid isPermaLink="false">http://www.moneymorning.com/?p=4629#comment-5113</guid>
		<description>[...] pharmaceutical industry has been a notable exception to the lull in Wall Street M&amp;A activity in 2009, largely because of its favored status among financial firms who have tightened the reins on [...]</description>
		<content:encoded><![CDATA[<p>[...] pharmaceutical industry has been a notable exception to the lull in Wall Street M&amp;A activity in 2009, largely because of its favored status among financial firms who have tightened the reins on [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Merck Stokes M&#38;A Fires with $41.1 Billion Bid for Schering-Plough</title>
		<link>http://moneymorning.com/2009/02/02/pfizer-wyeth/comment-page-1/#comment-5112</link>
		<dc:creator>Merck Stokes M&#38;A Fires with $41.1 Billion Bid for Schering-Plough</dc:creator>
		<pubDate>Mon, 09 Mar 2009 19:49:57 +0000</pubDate>
		<guid isPermaLink="false">http://www.moneymorning.com/?p=4629#comment-5112</guid>
		<description>[...] It&#8217;s the second mega-deal for Big Pharma this year, as Pfizer Inc. (PFE) made a $68 billion offer for Wyeth (WYE) in late January.&#160; Large pharmaceutical companies have been bucking a slide in M&amp;A activity that has been exceptionally quiet. [...]</description>
		<content:encoded><![CDATA[<p>[...] It's the second mega-deal for Big Pharma this year, as Pfizer Inc. (PFE) made a $68 billion offer for Wyeth (WYE) in late January.&nbsp; Large pharmaceutical companies have been bucking a slide in M&amp;A activity that has been exceptionally quiet. [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: The Market's Safest Sector Also Has Enormous Potential to Rise</title>
		<link>http://moneymorning.com/2009/02/02/pfizer-wyeth/comment-page-1/#comment-5109</link>
		<dc:creator>The Market's Safest Sector Also Has Enormous Potential to Rise</dc:creator>
		<pubDate>Fri, 06 Feb 2009 15:04:34 +0000</pubDate>
		<guid isPermaLink="false">http://www.moneymorning.com/?p=4629#comment-5109</guid>
		<description>[...] Money Morning Market Analysis:  The $68 Billion Pfizer-Wyeth Deal Won&#8217;t Revive the Moribund Merger Market. [...]</description>
		<content:encoded><![CDATA[<p>[...] Money Morning Market Analysis:  The $68 Billion Pfizer-Wyeth Deal Won't Revive the Moribund Merger Market. [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: David Allen</title>
		<link>http://moneymorning.com/2009/02/02/pfizer-wyeth/comment-page-1/#comment-5111</link>
		<dc:creator>David Allen</dc:creator>
		<pubDate>Mon, 02 Feb 2009 18:09:01 +0000</pubDate>
		<guid isPermaLink="false">http://www.moneymorning.com/?p=4629#comment-5111</guid>
		<description>02-02-09 The merger of Pfizer and Wyeth will be a disaster and is a vivid example of the events which caused the economic crisis.  All that is &quot;accomplished&quot; is 15M more people are unemployed and Wyeth&#039;s efforts to explore medical cares improvements through alternative medications will cease.  Pfizer and the FDA will maintain their strangle hold on &quot;approved&quot; medical treatment.</description>
		<content:encoded><![CDATA[<p>02-02-09 The merger of Pfizer and Wyeth will be a disaster and is a vivid example of the events which caused the economic crisis.  All that is "accomplished" is 15M more people are unemployed and Wyeth's efforts to explore medical cares improvements through alternative medications will cease.  Pfizer and the FDA will maintain their strangle hold on "approved" medical treatment.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Hot Stocks: Pfizer-Wyeth Merger Underscores That Bigger Isn't Better, Takeover Expert Basenese Says</title>
		<link>http://moneymorning.com/2009/02/02/pfizer-wyeth/comment-page-1/#comment-5110</link>
		<dc:creator>Hot Stocks: Pfizer-Wyeth Merger Underscores That Bigger Isn't Better, Takeover Expert Basenese Says</dc:creator>
		<pubDate>Mon, 02 Feb 2009 10:34:14 +0000</pubDate>
		<guid isPermaLink="false">http://www.moneymorning.com/?p=4629#comment-5110</guid>
		<description>[...] [Editor&#8217;s Note: Louis Basenese is a regular contributor to Money Morning, both as a writer and as an expert on the dealmaking market. To find out more about Basenese, or to check out his White Cap Report, please click here. For an overall analysis of the outlook for more buyouts in a story that appears elsewhere in today&#8217;s issue of Money Morning, please click here.] [...]</description>
		<content:encoded><![CDATA[<p>[...] [Editor&rsquo;s Note: Louis Basenese is a regular contributor to Money Morning, both as a writer and as an expert on the dealmaking market. To find out more about Basenese, or to check out his White Cap Report, please click here. For an overall analysis of the outlook for more buyouts in a story that appears elsewhere in today&rsquo;s issue of Money Morning, please click here.] [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>

